Article Sidebar

Submitted
May 9, 2021
Published
May 9, 2021
Download
PDF
Statistic
Read Counter : 57 Download : 30

Main Article Content

Abstract

Background


One of the most common manifestation of adverse drug reactions is cutaneous adverse drug reaction, which includes skin and it's appendages, mucous membranes, occurring with a wide variation in morphological pattern.


Aim


To know the incidence, patterns and causality of Cutaneous Adverse Drug Reactions (CADRs), reported at ADR Monitoring Centre (AMC), Guntur Medical College/GGH.


Materials & Methods


After obtaining Institutional Ethics Committee approval, 840 CADRs reported to ADR Monitoring Centre (AMC), Guntur, over a period of 3 years   were included in the study. For of each CADR - demographic details, suspected drug used, and concomitant medication details from their suspected Adverse Drug Reaction (sADR) reporting forms were taken.  Causality assessment was done for each CADR with the help of WHO Causality assessment scale. Descriptive statistics were applied for the results analysis. 


Results


Out of 840 CADRs, 567 (67.5%) occurred in females and 273 (32.5%) occurred in males. Age distribution ranged from 2 months to 75 years with a mean age of 37.09 + 12.74 SD years. 28 (3%) CADRs were serious and required hospitalization, 812(97%) CADRs were not serious and most of them were medically treated and recovered. 647 (77%) CADRs were due to antiretroviral drugs, 109 (13%) were due to anticancer drugs, 84 (10%) were due to antibacterial agents, NSAIDs, antiepileptics and other drugs. Maculopapular rash (58.6%) was the most common CADR observed in the study and other CADRs were pruritus (15%), mouth ulcerations (10.7%) etc. 


Conclusion


Most of the CADRs were due to antiretroviral drug combinations and anticancer drug combinations. To prevent and reduce the incidence of CADRs, development and implementation of various strategies is necessary.

Keywords

Cutaneous adverse drug reactions Maculopapular rash Causality assessment

Article Details

How to Cite
Dr. Vijaya Kumari Suryadevara. M.D, Dr. Meena Kumari Amancharla, M.D, & Mr. Pavan Kumar Kandula. Pharm D. (2021). Retrospective study of cutaneous adverse drug reactions reported at adverse drug reaction monitoring centre (AMC) at GMC/GGH, Guntur, Andhra - Pradesh, India. International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(3), 250-258. https://doi.org/10.61096/ijrpp.v7.iss3.2018.250-258
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Sengupta SR, Das NK. Cutaneous adverse drug reaction to systemic drugs: Recent updates. In: Ghosh S, editor. Recent Advances in Dermatology. New Delhi: Jaypee Brothers Medical Publishers; 1, 2004, 88-114.
  2. [2]. Mani AR, Rajendran AD, Suresh B. Adverse drug reaction monitoring in secondary care hospital in south India. Br J Clin Phormacol.65, 2007, 210-6.
  3. [3]. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 48(6), 1999, 839- 46.
  4. [4]. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital--their severity and cost involved. Pharmacoepidemiol Drug Saf.12, 2003, 687–92.
  5. [5]. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 137, 2001, 765–70.
  6. [6]. Martin T, Li H. Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J (Engl) 121, 2008, 756–61.
  7. [7]. Arulmani R, Rajendran SD, Suresh B. Adverse Drug Reaction Monitoring In A Secondary Care Hospital In South India. Br J Clin Pharmacol. 65(2), 2008, 210-6.
  8. [8]. Jose J. Rao PG. Pattern Of Adverse Drug Reactions Notified By Spontaneous Reporting In An Indian Tertiary Care Teaching Hospital. Pharmacol Res. 54(3), 2006, 226-33.
  9. [9]. Babu LN, Carounanidy U, Vasudevan KP, Sivagnanam G. Pattern of cutaneous adverse drug reactions at a tertiary care hospital in Southern India. Int J Basic Clin Pharmacol 6, 2017, 538-42.
  10. [10]. Qayoom S, Bisati S, Manzoor S, Sameem F, Khan K. Adverse cutaneous drug reactions- a clinicodemographic study in a tertiary care teaching hospital of the Kashmir Valley, India. Arch Iran Med. 18(4), 2015, 228-33.
  11. [11]. Pudukadan D, Thappa DM. Adverse cutaneous drug reactions : Clinical pattern and causative agents in a tertiary care centre in South India. Indian J Dermatol Venereol Leprol 70, 2004, 20-4.
  12. [12]. Saha A, Das NK, Hazra A, Gharami RC, Chowdhury SN, Datta PK. Cutaneous adverse drugreaction profile in a tertiary care out patient setting in Eastern India. Indian J Pharmacol 44, 2012, 792-7
  13. [13]. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions : Clinical pattern and causative agents - a 6 year series from Chandigarh, India. J Postgrad Med 47, 2001, 95-9.
  14. [14]. Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective. International Journal of Applied and Basic Medical Research. 1(1), 2011, 50-53. doi:10.4103/2229-516X.81982.
  15. [15]. Shah SP, Desai MK, Dikshit RK. Analysis of cutaneous adverse drug reactions at a tertiary care hospital – A prospective study. Trop J Pharm Res 10, 2011, 517-22.
  16. [16]. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 74, 2008, 430.
  17. [17]. Sharma R, Dogra D, Dogra N. A study of cutaneous adverse drug reactions at a tertiary center in Jammu, India. Indian Dermatol Online J 6, 2015, 168-71.
  18. [18]. Sushma M, Noel MV, Ritika MC, James J, Guido S. Cutaneous adverse drug reactions : A 9-year study from a South Indian Hospital. Pharmacoepidemiol Drug Saf 14, 2005, 567-70.
  19. [19]. Jhaj R, Uppal R, Malhotra S, Bhargava VK. Cutaneous adverse reactions in in-patients in a tertiary care
  20. hospital. Indian J Dermatol Venereol Leprol 65, 1999, 14-7.